Boeing secured FAA approval in late 2025 to ramp up 737 MAX output to 42 jets per month and has outlined plans to increase 787 Dreamliner production to 10 aircraft per month in 2026. The certification campaigns for the 737 MAX 7 and MAX 10 variants are on schedule, and flight testing for the 777-9 widebody continues ahead of a planned entry into service in 2027. These milestones follow years of constrained output after the 2018–2019 crashes and are critical to unlocking new revenue streams and rebuilding manufacturing credibility.

Boeing entered 2026 with a record order backlog exceeding $636 billion and recorded 1,173 net orders for 2025, surpassing Airbus’s 889 for the first time since 2018. Early in 2026, Alaska Airlines committed to up to 105 additional 737 MAX jets, while Delta Air Lines placed orders for up to 60 787 Dreamliners. These high-profile commitments underscore strong airline confidence and support projected annual deliveries of 600–650 aircraft.

Boeing shares have climbed approximately 9% year-to-date, rising from $227.77 at the start of 2026 to near $248 mid‐January, marking a two-year high. Trading volume during the recent breakout was 58% above average, indicating institutional interest. Wall Street analysts maintain a moderate buy consensus, with twelve-month price targets ranging from $237 to $300 and firms like Bernstein forecasting free cash flow of $9–10 billion annually by 2028.

As of December 2025, Boeing held $22.28 billion in cash against a debt-to-EBITDA ratio above 3x, compared with 1.2x for its European rival. Management projects positive free cash flow of $2.3 billion in 2026, rising to $6.8 billion in 2027. The company trades at a market capitalization of $194 billion, an enterprise value of $224 billion, a price-to-sales ratio of 2.31x and a forward P/E of 122x. Regulatory scrutiny, supply-chain integration challenges following the Spirit AeroSystems acquisition, and certification delays for new variants remain key risks to the recovery thesis.